2024-03-28T13:20:12Z
https://nagoya.repo.nii.ac.jp/oai
oai:nagoya.repo.nii.ac.jp:00013457
2023-11-16T06:36:58Z
499:508:509:1359
STRONG ANTIBODY REACTION AGAINST GLYCOSPHINGOLIPIDS INJECTED IN LIPOSOMEEMBEDDED FORMS IN β3GN-T5 KNOCKOUT MICE
FAN, XIAOYAN
KONDO, YUJI
TOKUDA, NORIYO
OHMI, YUHSUKE
ANDO, REIKO
UMEZU, TOMOKAZU
ZHANG, QING
FURUKAWA, KEIKO
SHIBATA, KIYOSUMI
TOGAYACHI, AKIRA
NARIMATSU, HISASHI
OKAJIMA, TETSUYA
KIKKAWA, KOJI
FURUKAWA, KOICHI
open access
Immunization
Antibody
Knockout
Glycolipids
Gangliosides
Liposome
It is known that mutant mice of the β-1,3-N-acetylglucosaminyltransferase gene (β3Gn-T5) respond well to T-cell dependent and independent antigens. Here, we examined the effectiveness of anti-ganglioside antibody generation by immunization of β3Gn-T5 mutant mice with liposome-embedded glycosphingolipids such as GD1a and GT1b. Consequently, the mutant mice showed a more efficient generation of anti-GD1a or anti-GT1b antibodies than wild-type mice in an enzyme-linked immunosorbent assay using sera during immunization. Thus, the β3Gn-T5 deficient mutant mice proved more responsive than wild-type mice to not only protein antigens, but also to carbohydrates in glycolipids. Furthermore, about 50% of monoclonal antibodies generated using splenocytes of the immunized mutant mice were of the IgG class. Besides general high responsiveness to proteins and glycolipids, it could be expected that the mutant mice of β3Gn-T5 would be useful in the generation of monoclonal antibodies towards lacto-/neolacto-series glycolipids, since these mutants lack lacto-/neolacto-series glycolipids. In fact, they showed a good serum response in immuno-fluorescence assay with cultured living cells when immunized by glycolipids extracted from ovarian cancer cell lines. These results suggested that β3Gn-T5 mutant mice are useful for the generation of anti-glycolipid antigens with lacto-/neolacto-core structures expressed in cancer cells.
Nagoya University School of Medicine
2011-08
eng
departmental bulletin paper
VoR
https://doi.org/10.18999/nagjms.73.3-4.137
http://hdl.handle.net/2237/15356
https://nagoya.repo.nii.ac.jp/records/13457
10.18999/nagjms.73.3-4.137
http://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/7334/7334.html
2186-3326
0027-7622
Nagoya Journal of Medical Science
73
3-4
137
146
https://nagoya.repo.nii.ac.jp/record/13457/files/v73n34p137_146.pdf
application/pdf
768.8 kB
2018-02-20